Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Read original reporting ↗← Story archive
Business
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Follow the evidence
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →